BioCentury
ARTICLE | Finance

Extra stuffing

Why LSP's newest European-focused life sciences fund is bursting at the seams

June 6, 2016 7:00 AM UTC

Inbound interest from a strategic investor and a basket of liquidity events from LSP's prior fund helped the firm close its newest fund at $280 million, which was the hard cap. The result of LSP exceeding its $170 million original target for LSP 5 is more cash for portfolio companies, rather than building a broader portfolio.

LSP's René Kuijten said LSP 5 will invest in 20 private companies, half of which will be drug developers. The remainder will be evenly split between medtech and diagnostics. About 80-90% of the investments will be in Europe, with a heavy focus on the Netherlands, Germany, Belgium and Switzerland...